EATG » Hepatitis

Hepatitis

Gilead Sciences and Precision BioSciences announce collaboration to develop therapies against hepatitis B virus using ARCUS genome editing

FOSTER CITY, Calif. & DURHAM, N.C., Sep. 12, 2018-- Gilead Sciences (Nasdaq: GILD) and Precision BioSciences announced today that the companies have entered into a strategic collaboration to develop therapies…

Groups call for end to Gilead’s unwarranted hepatitis C drug monopoly in Europe

Gilead’s price gouging for sofosbuvir blocks millions of people from getting treatment NEW YORK/MUNICH/PARIS, SEPTEMBER 11, 2018—This week in Munich, the European Patent Office (EPO) will hear a legal challenge…

Less than half of children born to mothers with hepatitis C tested for HCV, US study finds

Less than half of the children born to mothers with opioid dependency and hepatitis C were tested for hepatitis C between 2006 and 2015 in a large clinic providing antenatal…

Arrowhead presents new ARO-HBV clinical data demonstrating HBsAg reductions

Arrowhead presents new ARO-HBV clinical data demonstrating HBsAg reductions at World Gastroenterologists Summit -- Data presented from the lowest two dose cohorts (100mg and 200mg ARO-HBV) -- Up to 4.0…

Reinfection risk after hepatitis C treatment higher in recent drug users

Reinfection with hepatitis C after successful treatment is more common in younger people who inject drugs and recent and former drug users are at greatest risk of reinfection, a cohort…

Toward integrated care for hepatitis C infection and addiction

The World Health Organization's global strategy on viral hepatitis aims to reduce new infections by 90% by 2030.1 To meet that goal, increased effort is needed to engage people who inject…

Inovio and Korean partner dose 1st subject in trial to develop world’s first vaccine to prevent hepatitis C infection

While new therapies have made hepatitis C a curable infection, no preventive vaccine has ever been approved PLYMOUTH MEETING, Pa., and SEOUL, Korea, Sept. 04, 2018 -- Inovio Pharmaceuticals, Inc.…

HCV-positive liver transplant cost-effective in patients without HCV

Modelling results from a recent study showed that transplantation of hepatitis C-positive livers into uninfected patients with preemptive direct-acting antiviral therapy was a cost-effective strategy and could improve health outcomes,…

DAAs safe and effective in elderly people with HCV

Treatment with direct-acting antivirals (DAAs) is safe and effective in elderly people with hepatitis C virus (HCV) infection, according to German research published in Drugs & Aging. Elderly people (aged…

Viral hepatitis updates: 7 reports on risks, therapy pipelines

Direct-acting antiviral therapy has offered a highly effective cure for hepatitis C. Unfortunately, curative options are not yet available for other hepatitis viruses. Researchers continue their efforts to improve treatment…